Wake Dermatology Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2018
NCT03487549
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Wake Dermatology

Active Ingredients

Drugs in Phase 2 Trials (1)

cantharidin (Ycanth) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

DNA Virus Infections (Phase 2)

Infections (Phase 2)

Papillomavirus Infections (Phase 2)

Skin Diseases (Phase 2)

Skin Diseases, Infectious (Phase 2)

Skin Diseases, Viral (Phase 2)

Tumor Virus Infections (Phase 2)

Virus Diseases (Phase 2)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1